PR Newswire Clinical TrialsOriginal article
Chemo-Resistant Pancreatic Tumor Liquefies and Drains Several Months after Receiving Proprietary Intratumoral EpCAM/CD3 Vaccine
Data ReadoutpositiveEpCAM/CD3 VaccinegemcitabinePositive
AI Analysis
Summary
A peer-reviewed case report documents a chemo-resistant pancreatic tumor showing 90% volume reduction and extensive necrosis following treatment with an intratumoral EpCAM/CD3 vaccine, achieved without surgery or full-dose chemotherapy after gemcitabine failure.
Clinical Trial Data
Patients
1
Outcome Details
90% tumor volume reduction with extensive necrosis in chemo-resistant pancreatic tumor patient after intratumoral EpCAM/CD3 vaccine without surgery or full-dose chemotherapy
Importance:5/10
Sentiment:
0.70
pancreatic cancerimmunotherapycase reporttumor reductionintratumoral vaccine
Read the original article
Published by PR Newswire Clinical Trials on September 7, 2026 4:55 PM